Orexo AB (CHIX:ORXS) Cyclically Adjusted FCF per Share: kr-0.67 (As of Mar. 2026)


CHIX:ORXS Orexo AB CHIX:ORXS
37 GF Score
Price kr30.95
GF Value kr8.52
! 8 Warning Signs
View Full Analysis

What is Orexo AB Cyclically Adjusted FCF per Share?

Orexo AB CHIX:ORXS 37 Cyclically Adjusted FCF per Share is kr-0.67 as of Mar. 2026. GuruFocus rates CHIX:ORXS with a GF Score™ of 37/100 and a GF Value™ of kr8.52. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Orexo AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.844. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-0.67 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 57.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 35.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Orexo AB was 57.70% per year. The lowest was -27.20% per year. And the median was 21.40% per year.

As of today (2026-07-13), Orexo AB's current stock price is kr30.95. Orexo AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-0.67. Orexo AB's Cyclically Adjusted Price-to-FCF of today is .


Orexo AB  (CHIX:ORXs) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Orexo AB Cyclically Adjusted FCF per Share Related Terms


Orexo AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Orexo AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Cyclically Adjusted FCF per Share Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.23 -5.43 -4.60 -0.83 -0.26

Orexo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.30 -0.71 -0.18 -0.26 -0.67

CHIX:ORXS vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orexo AB's Cyclically Adjusted Price-to-FCF falls into.


CHIX:ORXS
37GF Score
Orexo AB CHIX:ORXS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orexo AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.844/133.5600*133.5600
=-0.844

Current CPI (Mar. 2026) = 133.5600.

Orexo AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.571 101.019 0.755
201609 0.870 101.138 1.149
201612 2.059 102.022 2.696
201703 0.808 102.022 1.058
201706 1.404 102.752 1.825
201709 2.648 103.279 3.424
201712 -0.686 103.793 -0.883
201803 3.066 103.962 3.939
201806 1.077 104.875 1.372
201809 0.683 105.679 0.863
201812 2.012 105.912 2.537
201903 1.442 105.886 1.819
201906 1.253 106.742 1.568
201909 3.449 107.214 4.297
201912 1.095 107.766 1.357
202003 1.251 106.563 1.568
202006 -3.278 107.498 -4.073
202009 -1.818 107.635 -2.256
202012 -1.201 108.296 -1.481
202103 -1.869 108.360 -2.304
202106 -0.990 108.928 -1.214
202109 -2.925 110.338 -3.541
202112 -2.428 112.486 -2.883
202203 -1.965 114.825 -2.286
202206 0.291 118.384 0.328
202209 -1.813 122.296 -1.980
202212 -1.775 126.365 -1.876
202303 -1.816 127.042 -1.909
202306 -0.683 129.407 -0.705
202309 -0.833 130.224 -0.854
202312 -0.102 131.912 -0.103
202403 -0.583 132.205 -0.589
202406 -0.267 132.716 -0.269
202409 -0.388 132.304 -0.392
202412 -2.617 132.987 -2.628
202503 -1.206 132.825 -1.213
202506 -0.018 133.699 -0.018
202509 -0.253 133.480 -0.253
202512 -0.680 133.390 -0.681
202603 -0.844 133.560 -0.844

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-0.67 mean?
Orexo AB (CHIX:ORXS) has a Cyclically Adjusted FCF per Share of kr-0.67 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orexo AB and its competitors.
Is Orexo AB's Cyclically Adjusted FCF per Share too high?
Orexo AB's current Cyclically Adjusted FCF per Share is kr-0.67. Overall, Orexo AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Orexo AB's Cyclically Adjusted FCF per Share of kr-0.67 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orexo AB and its competitors. Orexo AB's current Cyclically Adjusted FCF per Share is kr-0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Orexo AB (CHIX:ORXS) has a current Cyclically Adjusted FCF per Share of kr-0.67. The stock's GF Value™ is kr8.52, compared to a current price of kr30.95 — trading 263.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-0.67. Orexo AB's overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Orexo AB (CHIX:ORXS), the current Cyclically Adjusted FCF per Share is kr-0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (CHIX:ORXS) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr30.95 is trading 263.3% above its estimated GF Value™ of kr8.52.

Key valuation signals for CHIX:ORXS:

  • Cyclically Adjusted FCF per Share: kr-0.67
  • GF Value™: kr8.52 vs. price of kr30.95 (263.3% above fair value)
  • GF Score™: 37/100 with 8 warning signs

No single metric tells the full story. See the CHIX:ORXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
37GF Score

Get the complete analysis for CHIX:ORXS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr30.95
Price
kr8.52
GF Value